At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
Nilotinib +1 moredrug
Likely dose
Nilotinib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
In Brief
A Phase 2 clinical trial evaluating Nilotinib and DTIC for Melanoma. Completed, enrolled 55 participants across 49 sites in 14 countries.
Detailed Summary
The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesArgentina, Australia, Belgium, Brazil, Canada, China, Germany, Italy, Netherlands, Singapore, Spain, Sweden, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartJun 2010
Primary CompletionDec 2014
TodayJul 2026
First PostedDec 9, 2009
Enrollment StartJun 1, 2010
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 16.6 years ago
Interventions
Nilotinibdrug
Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
DTICdrug
DTIC was supplied locally as sterile powder for i.v. infusion.